{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:57:46Z","timestamp":1777413466035,"version":"3.51.4"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003785","name":"Medical Research Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["No. A2022362"],"award-info":[{"award-number":["No. A2022362"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Projects of Medical and Health Institutions of Longhua District Shenzhen","award":["No. 2021017"],"award-info":[{"award-number":["No. 2021017"]}]},{"name":"Shenzhen Science and Technology Planning Projec","award":["No. JCYJ20220530165014033"],"award-info":[{"award-number":["No. JCYJ20220530165014033"]}]},{"name":"Medical research project of Shenzhen Longhua Medical Association","award":["2023LHMA10"],"award-info":[{"award-number":["2023LHMA10"]}]},{"name":"Shenzhen Medical Key Discipline","award":["No. MKD202007090201"],"award-info":[{"award-number":["No. MKD202007090201"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:p>\n                    Growing evidence have indicated the bidirectional relationships between various inflammatory cytokines and prostate cancer (PCa), but the causality between genetic susceptibility to inflammatory cytokines and PCa was still in initial exploratory phase. This bidirectional Mendelian randomization (MR) research was manipulated to draw causative inferences and the effect of direction between 91 inflammatory cytokines and PCa. Genetic data of PCa were originated from a publicly accessible genome-wide association study with 3269 individuals and 459,664 controls, and inflammatory cytokines summarized by a protein quantitative trait locus study were embodied 14,824 participants. We considered inverse variance weighted as a primarily statistical approach, and utilized MR-Egger regression, weighted median, MR-PRESSO, and simulation extrapolation method to enhance the accuracy of the ultimate outcome. In sensitivity analysis, MR-Egger method and Cochran\n                    <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                    statistic of inverse variance weighted were employed to access the heterogeneity. The results suggested a causal relationship between fms-related tyrosine kinase 3 ligand (Flt3L), recombinant monocyte chemotactic protein (MCP) 2, MCP4, and the incidence of PCa (odds ratio [OR]: 1.0016, 95% confidence interval [CI]: 1.0000\u20131.0032,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.045; OR: 0.9979, 95% CI: 0.9958\u20131.0000,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.045; OR: 1.0012, 95% CI: 1.0001\u20131.0023,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.031). In addition, reverse analysis showed that PCa was correlated with the elevated level of adenosine deaminase, axin-1, C-X-C motif chemokine ligand 6, Flt3L, interleukin (IL)-24, and IL-33 (Beta: 1.7661, 95% CI: 0.2092\u20133.3229,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.026; Beta: 1.9185, 95% CI: 0.1548\u20133.6822,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.033; Beta: 1.9681, 95% CI: 0.4207\u20133.5155,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.013; Beta: 1.6589, 95% CI: 0.0733\u20133.2446,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.040; Beta: 2.2091, 95% CI: 0.4682\u20133.9500,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.013; Beta: 1.8438, 95% CI: 0.0815\u20133.6061,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005040). This study highlighted the causality between several inflammatory factors and the setting of PCa. Specifically, the results suggested that Flt3L and MCP4 may be risk factors for PCa, whereas MCP2 may be a favorable factor for PCa. Conversely, adenosine deaminase, axin-1, C-X-C motif chemokine ligand 6, IL-24, IL-33, and Flt3L were involved in the downstream of PCa progression.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044180","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:09:07Z","timestamp":1757354947000},"page":"e44180","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Investigating bidirectional causality between prostate cancer and inflammatory factors: A 2-sample Mendelian randomization analysis"],"prefix":"10.1097","volume":"104","author":[{"given":"Jieyan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Longhua, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Cheng","sequence":"additional","affiliation":[{"name":"College of Second Clinical Medicine, Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyu","family":"Luo","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4553-3300","authenticated-orcid":false,"given":"Yantong","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-8335","authenticated-orcid":false,"given":"Hui","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Urology, The People\u2019s Hospital of Longhua, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251029","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide.","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"R2-20251029","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s44197-023-00103-6","article-title":"Global burden of prostate cancer and association with socioeconomic status, 1990\u20132019: a systematic analysis from the Global Burden of Disease study.","volume":"13","author":"Zhang","year":"2023","journal-title":"J Epidemiol Glob Health"},{"key":"R3-20251029","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease study 2016.","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"R4-20251029","doi-asserted-by":"crossref","first-page":"14257","DOI":"10.3390\/ijms232214257","article-title":"Complexities of prostate cancer.","volume":"23","author":"Wasim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R5-20251029","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/ijms21041447","article-title":"Influence of diet and nutrition on prostate cancer.","volume":"21","author":"Matsushita","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"Pt 3","key":"R6-20251029","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.semcancer.2021.09.007","article-title":"Microbiota and prostate cancer.","volume":"86","author":"Rizzo","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R7-20251029","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrurol.2012.185","article-title":"The complexity of prostate cancer: genomic alterations and heterogeneity.","volume":"9","author":"Boyd","year":"2012","journal-title":"Nat Rev Urol"},{"key":"R8-20251029","doi-asserted-by":"crossref","first-page":"153440","DOI":"10.1016\/j.prp.2021.153440","article-title":"Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.","volume":"222","author":"Rizzo","year":"2021","journal-title":"Pathol Res Pract"},{"key":"R9-20251029","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer.","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R10-20251029","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/cancers14061367","article-title":"Inflammation and prostate cancer: a multidisciplinary approach to identifying opportunities for treatment and prevention.","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R11-20251029","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pros.23810","article-title":"Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.","volume":"79","author":"Xiang","year":"2019","journal-title":"Prostate"},{"key":"R12-20251029","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nucmedbio.2019.01.003","article-title":"Prostate cancer and inflammation: a new molecular imaging challenge in the era of personalized medicine.","volume":"68-69","author":"Schillaci","year":"2019","journal-title":"Nucl Med Biol"},{"key":"R13-20251029","doi-asserted-by":"crossref","first-page":"106669","DOI":"10.1016\/j.prostaglandins.2022.106669","article-title":"Physical exercise regulates apoptosis and prostatic inflammatory effects induced by high-fat diet in PPAR-alpha deleted mice.","volume":"163","author":"Tavares","year":"2022","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"R14-20251029","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.","volume":"22","author":"Crawford","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R15-20251029","first-page":"624","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data.","volume":"31","author":"Guven","year":"2023","journal-title":"Support Care Cancer"},{"key":"R16-20251029","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement.","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R17-20251029","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41467-019-14156-4","article-title":"A robust and efficient method for Mendelian randomization with hundreds of genetic variants.","volume":"11","author":"Burgess","year":"2020","journal-title":"Nat Commun"},{"key":"R18-20251029","first-page":"a041302","article-title":"Mendelian randomization.","volume":"12","author":"Birney","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R19-20251029","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-023-01588-w","article-title":"Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.","volume":"24","author":"Zhao","year":"2023","journal-title":"Nat Immunol"},{"key":"R20-20251029","doi-asserted-by":"crossref","first-page":"985729","DOI":"10.3389\/fimmu.2022.985729","article-title":"Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: a Mendelian randomization.","volume":"13","author":"Xiang","year":"2023","journal-title":"Front Immunol"},{"key":"R21-20251029","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"R22-20251029","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases.","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat Genet"},{"key":"R23-20251029","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/CIRCULATIONAHA.118.035905","article-title":"Genetically determined levels of circulating cytokines and risk of stroke: role of monocyte chemoattractant protein-1.","volume":"139","author":"Georgakis","year":"2019","journal-title":"Circulation"},{"key":"R24-20251029","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s40471-017-0128-6","article-title":"Recent developments in Mendelian randomization studies.","volume":"4","author":"Zheng","year":"2017","journal-title":"Curr Epidemiol Rep"},{"key":"R25-20251029","doi-asserted-by":"crossref","first-page":"e34408","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome.","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"R26-20251029","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/eurheartj\/ehz388","article-title":"Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study.","volume":"41","author":"Larsson","year":"2020","journal-title":"Eur Heart J"},{"key":"R27-20251029","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.3390\/cancers16213689","article-title":"Prognostic value of Neutrophil-to-Eosinophil Ratio (NER) in cancer: a systematic review and meta-analysis.","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R28-20251029","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3390\/jcm9082680","article-title":"Application of anti-inflammatory agents in prostate cancer.","volume":"9","author":"Hatano","year":"2020","journal-title":"J Clin Med"},{"key":"R29-20251029","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","article-title":"Prostate carcinogenesis: inflammatory storms.","volume":"20","author":"de Bono","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R30-20251029","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","article-title":"Molecular events in neuroendocrine prostate cancer development.","volume":"18","author":"Wang","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R31-20251029","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3390\/biomedicines10092116","article-title":"Inflammatory cytokine: an attractive target for cancer treatment.","volume":"10","author":"Lee","year":"2022","journal-title":"Biomedicines"},{"key":"R32-20251029","doi-asserted-by":"crossref","first-page":"586126","DOI":"10.3389\/fimmu.2020.586126","article-title":"Prostate cancer peripheral blood NK cells show enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 production and secrete monocyte-recruiting and polarizing factors.","volume":"11","author":"Gallazzi","year":"2021","journal-title":"Front Immunol"},{"key":"R33-20251029","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers13030546","article-title":"Bone targeting agents in patients with metastatic prostate cancer: state of the art.","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R34-20251029","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"R35-20251029","doi-asserted-by":"crossref","first-page":"1176639","DOI":"10.3389\/fimmu.2023.1176639","article-title":"CCL13 and human diseases.","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"R36-20251029","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10787-013-0177-5","article-title":"The multiple faces of CCL13 in immunity and inflammation.","volume":"21","author":"Mendez-Enriquez","year":"2013","journal-title":"Inflammopharmacology"},{"key":"R37-20251029","doi-asserted-by":"crossref","first-page":"154810","DOI":"10.1016\/j.cyto.2019.154810","article-title":"Extensive serum cytokine analysis in patients with prostate cancer.","volume":"125","author":"Gong","year":"2020","journal-title":"Cytokine"},{"key":"R38-20251029","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1089\/wound.2014.0594","article-title":"Chemokine regulation of angiogenesis during wound healing.","volume":"4","author":"Bodnar","year":"2015","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"R39-20251029","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3892\/ol.2021.13025","article-title":"Double-stranded RNA-specific adenosine deaminase-knockdown inhibits the proliferation and induces apoptosis of DU145 and PC3 cells by promoting the phosphorylation of H2A.X variant histone.","volume":"22","author":"Li","year":"2021","journal-title":"Oncol Lett"},{"key":"R40-20251029","doi-asserted-by":"crossref","first-page":"30555","DOI":"10.1038\/srep30555","article-title":"Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-33.","volume":"6","author":"Saranchova","year":"2016","journal-title":"Sci Rep"},{"key":"R41-20251029","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/ijms20081831","article-title":"Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and\/or enzalutamide therapy.","volume":"20","author":"Pal","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R42-20251029","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fonc.2020.00421","article-title":"Combination therapy of prostate cancer by oncolytic adenovirus harboring interleukin 24 and ionizing radiation.","volume":"10","author":"Mao","year":"2020","journal-title":"Front Oncol"},{"key":"R43-20251029","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.21873\/anticanres.13520","article-title":"Interleukin-24 transduction modulates human prostate cancer malignancy mediated by regulation of anchorage dependence.","volume":"39","author":"Maehana","year":"2019","journal-title":"Anticancer Res"},{"key":"R44-20251029","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/jcp.22904","article-title":"mda-7\/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.","volume":"227","author":"Bhutia","year":"2012","journal-title":"J Cell Physiol"},{"key":"R45-20251029","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/pros.22747","article-title":"Proteomic signatures of angiogenesis in androgen-independent prostate cancer.","volume":"74","author":"Karagiannis","year":"2014","journal-title":"Prostate"},{"key":"R46-20251029","doi-asserted-by":"crossref","first-page":"923307","DOI":"10.3389\/fonc.2022.923307","article-title":"A positive feedback loop between tryptophan hydroxylase 1 and \u03b2-Catenin\/ZBP-89 signaling promotes prostate cancer progression.","volume":"12","author":"Ge","year":"2022","journal-title":"Front Oncol"},{"key":"R47-20251029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00018-022-04207-3","article-title":"Mesenchymal stem cell-mediated transfer of mitochondria: mechanisms and functional impact.","volume":"79","author":"Velarde","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"R48-20251029","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","article-title":"Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy.","volume":"5","author":"Ghasemi","year":"2024","journal-title":"Nat Cancer"},{"key":"R49-20251029","doi-asserted-by":"crossref","first-page":"824459","DOI":"10.3389\/fimmu.2022.824459","article-title":"Fast maturation of splenic dendritic cells upon TBI is associated with FLT3\/FLT3L signaling.","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R50-20251029","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","article-title":"Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).","volume":"51","author":"Katoh","year":"2017","journal-title":"Int J Oncol"},{"key":"R51-20251029","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-9-49","article-title":"Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7\/IL-24 in prostate cancer.","volume":"9","author":"Ablin","year":"2011","journal-title":"J Transl Med"},{"key":"R52-20251029","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00262-020-02597-6","article-title":"Therapeutic ISCOMATRIX\u2122 adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer.","volume":"69","author":"Barr","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R53-20251029","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41467-022-29235-2","article-title":"Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer.","volume":"13","author":"Minas","year":"2022","journal-title":"Nat Commun"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:02:47Z","timestamp":1761750167000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":53,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044180","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"2025-01-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}